TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion.

Implications: Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab, Orencia, Rituximab . Biologics are typically reserved for patients with moderate to severe RA who require add-on therapy, estimated to be approximately 40 percent of the RA population. SBI-087 in phase-1 clinical trial to evaluate safety, tolerability , pharmacodynamics in RA with function class I, II or III diagnosed more than six month prior to surgery. Mechanisms Of Action: Therapeutic monoclonal antibodies (mAbs) typically act through three significant potential mechanisms of action: • Complement dependent cytotoxicity (CDC) • Antibody-dependent cellular cytotoxicity (ADCC) • Apoptosis (programmed cell death) All CD20-directed mAb therapies result in temporary B-cell depletion.

Analysis: SBI-087 in phase-1 clinical trial and  TRu-015 already showing good Data with good sample study population.


Being B cell depletor , competitive product for Orencia and Rituximab which affects the market for all companies including enbrel, humira, Ramicade companies.

As well as depending on Side effect issues No monoclonal Ab formation , so No dose escalation required that frequently. less vials in use , with same market and money and same benifits and efficacy. Benifits to company as well as patients and also insurance companies.